Anti-Human CD59 Recombinant Antibody ((ch)AR36A36.11.1) (CAT#: TAB-321LC)

Figure 1 demonstrates the effect of AR36 A36.11.1 on tumor growth in an established human PC-3 prostate cancer model. The vertical dashed lines indicate the period during which the antibody was intraperitoneally administered. Data points represent the mean +/- SEM.

Figure 2 demonstrates the effect of AR36A36.11.1 on tumor growth in an established human breast MDA-MB-468 cancer model. The vertical dashed lines indicate the period during which the antibody was intraperitoneally administered. Data points represent the mean +/- SEM.

Figure 3 demonstrates the effect of AR36A36.11.1 in a dose-response manner on tumor growth in an established human breast (MDA-MB-231) cancer model. The vertical dashed lines indicate the period during which the antibody was intraperitoneally administered. Data points represent the mean +/- SEM.

Figure 4 demonstrates effect of AR36A36.11.1 on mouse survival in a prophylactic NCI-H520 human lung squamous cell carcinoma model. Data points represent the survival percentage.

Figure 5 Western blot of a total membrane preparation of MDA-MB-231 breast cancer cells probed with different primary antibody solutions.

Lanes 3 to 7 were probed with biotinylated AR36A36.11.1 mixed with 0.5 micrograms/mL, 5 micrograms/mL, 50 micrograms/mL, 500 micrograms/mL and 1000 micrograms/mL of non-biotinylated AR36A36.11.1 respectively. Lanes 9-13 were probed with biotinylated AR36A36.11.1 mixed with 0.5 micrograms/mL, 5 micrograms/mL, 50 micrograms/mL, 500 micrograms/mL and 1000 micrograms/mL of non-biotinylated 10 A304.7 respectively. Lanes 15-19 were probed with biotinylated AR36A36.11.1 mixed with 0.5 micrograms/mL, 5 micrograms/mL, 50 micrograms/mL, 500 micrograms/mL and 1000 micrograms/mL of non-biotinylated 8BlB.1 respectively.

Figure 6 demonstrates the binding of humanized variants, chimeric and murine AR36A36.11.1 to the human breast cancer cell line MDA-MB-231.